BR112019022307A2 - Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. - Google Patents

Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. Download PDF

Info

Publication number
BR112019022307A2
BR112019022307A2 BR112019022307-0A BR112019022307A BR112019022307A2 BR 112019022307 A2 BR112019022307 A2 BR 112019022307A2 BR 112019022307 A BR112019022307 A BR 112019022307A BR 112019022307 A2 BR112019022307 A2 BR 112019022307A2
Authority
BR
Brazil
Prior art keywords
patient
pirrolopyrimidine
virus replication
derivatives useful
replication inhibitors
Prior art date
Application number
BR112019022307-0A
Other languages
English (en)
Inventor
C. Jacobson Irina
David Feese Michael
Sk Lee Sam
Original Assignee
Cocrystal Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma, Inc. filed Critical Cocrystal Pharma, Inc.
Publication of BR112019022307A2 publication Critical patent/BR112019022307A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos para inibir a replicação de vírus da influenza em uma amostra biológica ou um paciente, para reduzir a quantidade de vírus da influenza em uma amostra biológica ou um paciente e para tratar influenza em um paciente compreendem administrar à referida amostra biológica ou ao paciente uma quantidade segura e eficaz de um composto representado por qualquer das fórmulas i-iii, ou um sal farmaceuticamente aceitável do mesmo. uma composição farmacêutica compreende uma quantidade segura e eficaz de tal composto ou sal farmaceuticamente aceitável do mesmo e um transportador, adjuvante ou veículo farmaceuticamente aceitável.
BR112019022307-0A 2017-04-24 2018-04-24 Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. BR112019022307A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489167P 2017-04-24 2017-04-24
US62/489,167 2017-04-24
PCT/US2018/028986 WO2018200425A1 (en) 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Publications (1)

Publication Number Publication Date
BR112019022307A2 true BR112019022307A2 (pt) 2020-05-26

Family

ID=62117141

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022307-0A BR112019022307A2 (pt) 2017-04-24 2018-04-24 Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.

Country Status (19)

Country Link
US (1) US11014941B2 (pt)
EP (1) EP3615545B1 (pt)
JP (1) JP7165721B2 (pt)
KR (1) KR102598466B1 (pt)
CN (1) CN110637022B (pt)
AU (1) AU2018257778B2 (pt)
BR (1) BR112019022307A2 (pt)
CA (1) CA3059449A1 (pt)
DK (1) DK3615545T3 (pt)
EA (1) EA039181B1 (pt)
ES (1) ES2901875T3 (pt)
IL (1) IL269900B (pt)
MX (1) MX2019012759A (pt)
NZ (1) NZ757442A (pt)
PH (1) PH12019502376A1 (pt)
PL (1) PL3615545T3 (pt)
SG (1) SG11201909478UA (pt)
TW (1) TWI778052B (pt)
WO (1) WO2018200425A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004215A (es) * 2018-10-17 2021-07-15 Cocrystal Pharma Inc Combinaciones de inhibidores de la replicación del virus de la gripe.
AU2019380421A1 (en) * 2018-11-13 2021-06-03 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
CN113748103A (zh) * 2019-04-26 2021-12-03 日产化学株式会社 芳基磺酸酯化合物的制造方法
CN115698011B (zh) * 2020-07-10 2023-10-20 四川海思科制药有限公司 Pb2抑制剂及其制备方法和用途
WO2022109495A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of California Methods and compositions for linking rna stem loops

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB278965A (en) 1927-03-24 1927-10-20 Gerhard Haar Improved agricultural plough
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
IE56059B1 (en) 1982-10-08 1991-04-10 Glaxo Group Ltd Devices for administering medicaments to patients
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
DE69031279T2 (de) 1989-12-05 1998-03-19 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6596296B1 (en) 1999-08-06 2003-07-22 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002013897A2 (en) 2000-08-14 2002-02-21 Advanced Inhalation Research, Inc. Inhalation device and method
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
WO2003015798A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
DK1455755T3 (da) 2001-11-20 2013-07-15 Civitas Therapeutics Inc Forbedrede partikelsammensætning til levering i lunge
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US8001963B2 (en) 2003-09-05 2011-08-23 Kurve Technology, Inc. Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
RU2403252C2 (ru) 2004-03-30 2010-11-10 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ
NZ601687A (en) 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
EP3351552B1 (en) 2012-03-13 2021-05-19 Gilead Sciences, Inc. 2'-substituted carba-nucleoside analogs for antiviral treatment
RS57541B1 (sr) * 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
MX2017002972A (es) 2014-09-08 2017-05-30 Janssen Sciences Ireland Uc Pirrolopirimidinas para usarse en la infeccion por el virus de la gripe.
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
FR3039227B1 (fr) 2015-07-22 2019-12-27 Safran Aircraft Engines Aeronef comprenant un propulseur arriere carene avec stator d’entree a volets mobiles
SG11201804225PA (en) * 2015-12-09 2018-06-28 Sunshine Lake Pharma Co Ltd Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017198122A1 (zh) 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
DE102017000989A1 (de) * 2017-02-03 2018-08-09 Evonik Degussa Gmbh Verfahren zur Herstellung von Cyclododecanon

Also Published As

Publication number Publication date
DK3615545T3 (da) 2021-11-22
WO2018200425A1 (en) 2018-11-01
US11014941B2 (en) 2021-05-25
MX2019012759A (es) 2019-12-16
EP3615545A1 (en) 2020-03-04
AU2018257778B2 (en) 2022-02-17
KR102598466B1 (ko) 2023-11-03
CA3059449A1 (en) 2018-11-01
CN110637022A (zh) 2019-12-31
IL269900B (en) 2022-05-01
JP2020517738A (ja) 2020-06-18
CN110637022B (zh) 2022-09-16
EA201992543A1 (ru) 2020-03-24
NZ757442A (en) 2022-10-28
EA039181B1 (ru) 2021-12-15
EP3615545B1 (en) 2021-09-01
JP7165721B2 (ja) 2022-11-04
SG11201909478UA (en) 2019-11-28
TWI778052B (zh) 2022-09-21
KR20190140971A (ko) 2019-12-20
US20200123177A1 (en) 2020-04-23
ES2901875T3 (es) 2022-03-24
PL3615545T3 (pl) 2022-01-10
AU2018257778A1 (en) 2019-10-10
TW201839003A (zh) 2018-11-01
PH12019502376A1 (en) 2020-09-14

Similar Documents

Publication Publication Date Title
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018006276A2 (pt) composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
EA201992295A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]